Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Annu Int Conf IEEE Eng Med Biol Soc ; 2019: 5877-5881, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-31947187

RESUMO

In this paper we propose a sensor embedded knee brace to monitor knee flexion and extension and other lower limb joint kinematics after anterior cruciate ligament (ACL) injury. The system can be easily attached to a standard post-surgical brace and uses a novel sensor fusion algorithm that does not require calibration. The wearable system and the sensor fusion algorithm were validated for various physical therapy exercises against a validated motion capture system. The proposed sensor fusion algorithm demonstrated significantly lower root-mean-square error (RMSE) than the benchmark Kalman filtering algorithm and excellent correlation coefficients (CCC and ICC). The demonstrated error for most exercises was lower than other devices in the literature. The quantitative measures obtained by this system can be used to obtain longitudinal range-of-motion and functional biomarkers. These biomarkers can be used to improve patient outcomes through the early detection of at-risk patients, tracking patient function outside of the clinic, and the identification of relationships between patient presentation, intervention, and outcomes.


Assuntos
Lesões do Ligamento Cruzado Anterior/cirurgia , Braquetes , Articulação do Joelho/fisiologia , Joelho/fisiologia , Algoritmos , Fenômenos Biomecânicos , Humanos , Joelho/cirurgia , Amplitude de Movimento Articular
2.
Ann Intern Med ; 128(12 Pt 1): 975-81, 1998 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-9625683

RESUMO

BACKGROUND: Hepatic complications are a major cause of illness and death after bone marrow transplantation. OBJECTIVE: To confirm the results of a pilot study that indicated that ursodiol prophylaxis could reduce the incidence of veno-occlusive disease of the liver. DESIGN: Randomized, double-blind, placebo-controlled study. SETTING: Tertiary care teaching hospital. PATIENTS: 67 consecutive patients undergoing transplantation with allogeneic bone marrow (donated by a relative) in whom busulfan plus cyclophosphamide was used as the preparative regimen and cyclosporine plus methotrexate was used to prevent graft-versus-host disease. INTERVENTION: Before the preparative regimen was started, patients were randomly assigned to receive ursodiol, 300 mg twice daily (or 300 mg in the morning and 600 mg in the evening if body weight was > 90 kg), or placebo. MEASUREMENTS: Patients were prospectively evaluated for the clinical diagnosis of veno-occlusive disease, the occurrence of acute graft-versus-host disease, and survival. RESULTS: The incidence of veno-occlusive disease was 40% (13 of 32 patients) in placebo recipients and 15% (5 of 34 patients) in ursodiol recipients (P = 0.03). Assignment to placebo was the only pretransplantation characteristic that predicted the development of veno-occlusive disease. The most significant predictor of 100-day mortality was the diagnosis of veno-occlusive disease. The difference in actuarial risk for hematologic relapse in patients with chronic myelogenous leukemia and nonhepatic toxicities between the two groups was not statistically significant (13% in the ursodiol group and 20% in the placebo group; P > 0.2). CONCLUSION: Ursodiol prophylaxis seemed to decrease the incidence of hepatic complications after allogeneic bone marrow transplantation in patients who received a preparative regimen with busulfan plus cyclophosphamide.


Assuntos
Transplante de Medula Óssea/efeitos adversos , Colagogos e Coleréticos/uso terapêutico , Hepatopatia Veno-Oclusiva/prevenção & controle , Ácido Ursodesoxicólico/uso terapêutico , Adulto , Transplante de Medula Óssea/mortalidade , Bussulfano/uso terapêutico , Ciclofosfamida/uso terapêutico , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Doença Enxerto-Hospedeiro/prevenção & controle , Humanos , Imunossupressores/uso terapêutico , Masculino , Pessoa de Meia-Idade , Placebos , Taxa de Sobrevida , Transplante Homólogo
4.
Bone Marrow Transplant ; 10(4): 367-72, 1992 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-1422493

RESUMO

Ursodiol is a hydrophilic, non-hepatotoxic bile salt indicated for the medical treatment of cholesterol gallstones. This pilot study explored the use of prophylactic ursodiol in an attempt to decrease the incidence and severity of veno-occlusive disease (VOD) of the liver following allogeneic bone marrow transplantation (BMT). Between February 1991 and January 1992, 22 consecutive patients undergoing BMT for hematologic malignancies received the BU(4)/CY(2) preparative regimen and CSA/MTX for GVHD prophylaxis. Ursodiol, 600-900 mg daily by mouth was begun at least 1 day prior to beginning the preparative regimen. Results for this pilot group were compared to a control group of 28 consecutive patients transplanted between June 1989 and January 1991 with the same regimen without ursodiol. There were no significant differences in disease or clinical status between the groups pretransplant. However, mean baseline AST levels were significantly higher in the ursodiol group, 28.0 U/l vs 18.1 U/l in the control group (p = 0.001). The median maximum bilirubin observed post-transplant was 2.35 mg/dl (range 0.9-45) in the ursodiol group, and 5.05 mg/dl (range 0.7-29.4) in controls. The incidence of VOD was 2/22 (9.1%) in the ursodiol group and 18/28 (64.3%) in controls (p = 0.0001). Death due to VOD occurred in 1/22 patients (4.5%) in the ursodiol group and in 6/28 (21.4%) controls (p = 0.12). Our data suggest that ursodiol may decrease the incidence of VOD in allogeneic BMT patients.


Assuntos
Transplante de Medula Óssea/efeitos adversos , Hepatopatia Veno-Oclusiva/prevenção & controle , Ácido Ursodesoxicólico/farmacologia , Adolescente , Adulto , Criança , Feminino , Hepatopatia Veno-Oclusiva/etiologia , Humanos , Leucemia/cirurgia , Masculino , Pessoa de Meia-Idade , Transplante Homólogo
5.
Blood ; 79(10): 2784-8, 1992 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-1586725

RESUMO

The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation. We report 87 patients prepared for allogeneic transplant with busulfan 4 mg/kg/d orally for 4 days, followed by cyclophosphamide 60 mg/kg/d intravenously for 2 days (Bu4Cy2). A marked increase in hepatotoxicity was observed in 20 patients administered CyA/MTX, compared with 67 historical control patients who received CyA/methylprednisolone (CyA/MP) for GVHD prophylaxis with all other treatment and support variables remaining constant. The incidence of hyperbilirubinemia (bilirubin greater than or equal to 2 mg/dL) increased from 48% to 80% (P = .02), and the mean maximal bilirubin increased from 4.67 +/- 7.27 to 8.72 +/- 8.73 mg/dL (P = .04), when CyA/MTX was used in place of CyA/MP for GVHD prophylaxis. In addition, the incidence of veno-occlusive disease (VOD) increased from 18% to 70% (P = .0001), and death caused by VOD increased from 4.5% to 25% (P = .02). Survival was not significantly different for the two groups because of a higher non-VOD death rate in patients receiving CyA/MP for GVHD prophylaxis (P = .77). We suggest caution when using Bu4Cy2 in combination with CyA/MTX for GVHD prophylaxis.


Assuntos
Transplante de Medula Óssea/imunologia , Bussulfano/uso terapêutico , Ciclofosfamida/uso terapêutico , Doença Enxerto-Hospedeiro/prevenção & controle , Hepatopatia Veno-Oclusiva/induzido quimicamente , Leucemia/cirurgia , Metotrexato/efeitos adversos , Metotrexato/uso terapêutico , Metilprednisolona/uso terapêutico , Análise Atuarial , Adulto , Transplante de Medula Óssea/métodos , Bussulfano/efeitos adversos , Feminino , Seguimentos , Humanos , Leucemia Mielogênica Crônica BCR-ABL Positiva/cirurgia , Leucemia Mieloide Aguda/cirurgia , Masculino , Metilprednisolona/efeitos adversos , Leucemia-Linfoma Linfoblástico de Células Precursoras/cirurgia , Fatores de Tempo , Irradiação Corporal Total
6.
Arch Dermatol ; 126(1): 73-7, 1990 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-2404465

RESUMO

A 31-year-old Hispanic man presented in the pancytopenic phase of acute myelocytic leukemia and was treated with the chemotherapeutic agents mitoxantrone and cytarabine. After 5 days, an erythematous, blanching, papular, crusted eruption developed on his forehead, chest, and legs. Some lesions showed confluence and all were at the same developmental stage. Clinical diagnoses included necrotizing vasculitis and sepsis. A biopsy specimen revealed widespread noninflammatory syringometaplasia of eccrine ducts. Well-developed intercellular bridges and eosinophilic cytoplasm were seen within the metaplastic cells; apoptoses and occasional mitoses were present. This process is distinct and probably occurred secondary to direct toxic injury from the chemotherapeutic drugs. Because similar changes have occurred in patients with neutrophilic eccrine hidradenitis, we believe our patient represents an example of the noninflammatory end of the spectrum of chemotherapeutic eccrine gland reactions.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Glândulas Écrinas/efeitos dos fármacos , Glândulas Sudoríparas/efeitos dos fármacos , Adulto , Atrofia , Citarabina/efeitos adversos , Glândulas Écrinas/patologia , Humanos , Inflamação , Leucemia Mieloide Aguda/tratamento farmacológico , Masculino , Mitoxantrona/efeitos adversos , Glândulas Sudoríparas/patologia
7.
Artigo em Inglês | MEDLINE | ID: mdl-7037712

RESUMO

The interrelationships of glucagon and insulin with the sympathetic system on glucose turnover during exercise were examined in sheep. Six sheep were run for 45 min on a treadmill with and without alpha- and/or beta-adrenergic blockade. The exercise-induced increase in glucose appearance, as assessed by infusion of [2-3H]glucose, was reduced during the first 25 min of exercise by phentolamine administration. The metabolic clearance rate of glucose also was greater during exercise with phentolamine treatment than without. Phentolamine was associated with a rise in insulin concentrations and appeared to delay the exercise-induced rise in glucagon. Propranolol administration had no effect on glucose turnover and plasma glucagon and insulin. Nor did it have any effect on the changes in glucose, insulin, or glucagon induced by phentolamine administration. These observations are consistent with the alpha-adrenergic mediation of the sympathetic influences on insulin and glucagon secretion, which may account in part for the glucose adaptations to exercise in sheep. However, direct affects of circulating catecholamines on and increased stimulation of sympathetic innervation to the liver cannot be ruled out.


Assuntos
Glucagon/sangue , Glucose/metabolismo , Insulina/sangue , Esforço Físico , Simpatolíticos/farmacologia , Animais , Glicemia/análise , Fentolamina/farmacologia , Propranolol/farmacologia , Ovinos
8.
Aust J Biol Sci ; 34(5-6): 551-60, 1981.
Artigo em Inglês | MEDLINE | ID: mdl-6122438

RESUMO

This study was conducted to characterize the mechanisms of hyperglycaemia in exercising sheep. Sheep were run on a treadmill for 45 min (5.5 km h-1, 8% incline) during adrenergic blockade (propranolol or phentolamine mesylate infusions) and during suppression of the rise in glucagon by infusion of somatostatin (SRIF). Propranolol did not alter the glucagon, insulin or glucose responses, except it tended to increase the metabolic clearance of glucose, presumably as a result of blocking the beta-adrenergic inhibition of glucose uptake. Phentolamine mesylate administration was associated with a suppression of the rise in glucagon concentrations, a reversal of alpha-adrenergic inhibition of insulin release and a reduction in glucose appearance during exercise. SRIF prevented the rise in glucagon and reduced insulin concentrations to below resting values. Propranolol and phentolamine mesylate did not alter the glucagon, insulin or glucose response to SRIF. However, SRIF prevented the insulin rise that occurred during phentolamine administration. The increment in glucose appearance produced in response to exercise was the same for SRIF, plus phentolamine mesylate and phentolamine mesylate in the first 25 min of exercise, but was significantly less than in the controls. During the last 20 min of exercise, glucose appearance was not significantly different from the control for any of the groups. The depression by SRIF and alpha-adrenergic blockade of the increment in glucose appearance due to exercise was associated with an impairment of the glucagon response. It appears, therefore, that glucagon may stimulate glucose production early in exercise in sheep directly, as well as by having a permissive effect.


Assuntos
Glicemia/metabolismo , Glucagon/sangue , Insulina/sangue , Fentolamina/farmacologia , Esforço Físico , Propranolol/farmacologia , Somatostatina/farmacologia , Animais , Taxa de Depuração Metabólica , Ovinos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...